Aberdeen Group
RCKT icon

Aberdeen Group’s Rocket Pharmaceuticals RCKT Stock Holding History

Aberdeen Group’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.36M Sell
397,727
-267,094
-40% -$888K ﹤0.01% 812
2026
Q1 		$2.38M Buy
+664,821
New +$2.64M ﹤0.01% 755

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Aberdeen Group's RCKT Position: Q2 2026 in Review

Aberdeen Group reduced its Rocket Pharmaceuticals (RCKT) stake by 40% in Q2 2026, selling an estimated $888K and leaving 397,727 shares worth $1.36M. The position accounts for ﹤0.01% of the portfolio, ranked #812.

Aberdeen Group first reported a position in RCKT in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.38M in Q1 2026. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Aberdeen Group held 397,727 shares of Rocket Pharmaceuticals worth $1.36M as of Q2 2026.
  • Aberdeen Group sold 267,094 Rocket Pharmaceuticals shares in Q2 2026, an estimated $888K.
  • Rocket Pharmaceuticals made up ﹤0.01% of Aberdeen Group's portfolio in Q2 2026, its #812 holding.
  • Aberdeen Group first reported a position in Rocket Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Aberdeen Group's Rocket Pharmaceuticals position peaked at $2.38M in Q1 2026.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.